NFKB1 and breast carcinoma: Because most of the breast cancer cell lines tested appeared to be TRAIL resistant [27,28], NF-kB targeting strategies involving IKK inhibition was employed to verify whether MCF7 breast carcinoma cells were sensitized to TRAIL under these circumstances.